# N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

> **NCT07217496** · PHASE1 · WITHDRAWN · sponsor: **Vadim S Koshkin**

## Conditions studied

- Metastatic Urothelial Carcinoma
- Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma
- Urothelial Cancer

## Interventions

- **DRUG:** Nogapendekin Alfa Inbakicept (N803)
- **DRUG:** Enfortumab Vedotin (EV)
- **DRUG:** Pembrolizumab
- **PROCEDURE:** Research Biospecimen Collection
- **PROCEDURE:** Radiographic Imaging
- **PROCEDURE:** Tumor Biopsy

## Key facts

- **NCT ID:** NCT07217496
- **Lead sponsor:** Vadim S Koshkin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-02-15
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07217496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07217496, "N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07217496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*